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Vascular endothelial growth factor (VEGF) is es-
sential for developmental and pathological an-
giogenesis. Here we show that in the absence
of any pathological insult, autocrine VEGF is re-
quired for the homeostasis of blood vessels in
the adult. Genetic deletion of vegf specifically
in the endothelial lineage leads to progressive
endothelial degeneration and sudden death in
55% of mutant mice by 25 weeks of age. The
phenotype is manifested without detectable
changes in the total levels of VEGF mRNA or
protein, indicating that paracrine VEGF could
not compensate for the absence of endothelial
VEGF. Furthermore, wild-type, but not VEGF
null, endothelial cells showed phosphorylation
of VEGFR2 in the absence of exogenous
VEGF. Activation of the receptor in wild-type
cells was suppressed by small molecule antag-
onists but not by extracellular blockade of
VEGF. These results reveal a cell-autonomous
VEGF signaling pathway that holds significance
for vascular homeostasis but is dispensable for
the angiogenic cascade.
INTRODUCTION
Genetic ablation experiments in mice have demonstrated
that vascular endothelial growth factor (VEGF) is critical to
the differentiation of endothelial cells and morphogenesis
of the vascular system during development. In fact, a sin-
gle vegf allele is insufficient to establish a proper vascular
network and mice die early in embryogenesis (Carmeliet
et al., 1996; Ferrara et al., 1996). Excess VEGF (by only
2-fold) also results in embryonic lethality, reiterating the
significance of vegf gene dosage during development (Mi-
querol et al., 2000). In the adult, ample experimental evi-dence has unequivocally shown that VEGF is required
for pathological growth of vessels in many conditions in-
cluding inflammation, retinopathies, and arthritis (Dvorak,
2006; Hicklin and Ellis, 2005; Folkman, 2007). Further-
more, the dependency of tumor expansion on neovascu-
larization has served to propel investigations aimed at
suppressing VEGF signaling by targeting either the ligand
or its receptors (Ferrara and Kerbel, 2005).
VEGF acts through two high-affinity receptor tyrosine
kinases, VEGFR1/flt-1 and VEGFR2/KDR/flk-1; both are
expressed on normal vascular endothelial cells (Mustonen
and Alitalo, 1995) and are upregulated during angiogene-
sis (Dvorak et al., 1999). VEGFR2 is thought to mediate
most of the angiogenic functions attributed to VEGF,
whereas the role of VEGFR1 signaling is less clear and
generally considered to be a decoy receptor, at least dur-
ing development (Zeng et al., 2001). Most of the VEGF iso-
forms also bind to a third, nontyrosine kinase receptor on
vascular endothelium, neuropilin-1 (Soker et al., 1998).
Neuropilin contributes to the sum of proangiogenic func-
tions mediated by VEGFR2, and it might also participate
in endothelial guidance and vascular patterning (Gerhardt
et al., 2004).
Notably, as a proangiogenic cytokine, the significance
of VEGF is unquestionable. However this is not its only
function. VEGF was originally discovered for its effects
on vascular permeability (Senger et al., 1983). Subdermal
injection of VEGF results in microvascular hyperperme-
ability, which leads to clotting of extravasated plasma fi-
brinogen and edema (Senger et al., 1983). More recently,
VEGF has also been shown to be required for mainte-
nance of the differentiated phenotype in endothelial cells.
In particular, the presence of endothelial fenestrations in
the pancreatic islands and glomeruli is dependent on con-
stitutive signaling through VEGF (Kamba et al., 2006).
However, the function of VEGF in nonpathological adult
tissues remains largely unknown, despite its biological
and therapeutic significance. In this study, we investi-
gated the functional relevance of endothelial-derived
VEGF in vivo.Cell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc. 691
RESULTS
VEGF Is Expressed by Endothelial Cells In Vivo
VEGF has been recognized as a paracrine factor in both
developmental and pathological settings. Although ex-
pression of VEGF has been found in endothelial cultures
under hypoxia (Namiki et al., 1995), the synthesis of
VEGF by endothelial cells in vivo was only reported re-
cently. Even then, its relevance has remained question-
able due to its spotty expression (Maharaj et al., 2006).
We expanded those evaluations to include nine organs
at three ages in two independent reporter models (Damert
et al., 2002; Miquerol et al., 2000) by X-gal staining. These
studies demonstrated frequent vegf promoter activity in
the endothelium of large and small vessels. Expression
was noted in normal adult mice (Figure 1A, arrows), sug-
gesting the presence of an autocrine signaling loop in
adult nonpathological vessels.
Generation and Analysis of VE-Cadherin-
Cre/VEGFlox/lox Mice
To elucidate the biological significance of VEGF expres-
sion by vascular endothelial cells in vivo, VE-Cadherin-
Cre (VE-CAD-Cre) transgenic mice (Alva et al., 2006)
were crossed to VEGFlox/lox mice (Gerber et al., 1999) to
generate VE-CAD-Cre/VEGFlox/+ mice. These were fur-
ther crossed with VEGFlox/lox to obtain VE-CAD-Cre/
VEGFlox/lox mice (referred to as VEGFECKO) (Figure 1B).
Specificity of Cre excision was assessed by crossing
VEGFECKO mice to the Rosa26R reporter (Soriano,
1999) line followed by X-gal staining of endothelial cells
isolated from control and VEGFECKO mice (Figure 1C). Us-
ing this approach, we found that more than 95% of the
cells in culture showed Cre activity and lacked vegf tran-
scripts (as per real-time RT-PCR results in Figure 6F). As
a control, X-gal staining was performed on endothelial
cells isolated from mice without the Cre transgene
(Figure 1C).
We genotyped 261 mice resulting from 35 litters of
crosses between VE-CAD-Cre/VEGFlox/+ mice. Analysis
of the resulting genotypes revealed a lower Mendelian fre-
quency for VEGFECKO mice (18.7% shown versus 25%
expected, Table S1). Evaluation of the viability profile for
VEGFECKO showed that 31.6% died in utero, 11.5% of
newborn mice died between P0 and P5, and 26.1%
died between 4 weeks and 6 months (Figure 1D). A cohort
of mice was followed for 6 months to ascertain whether
lethality occurred at a particular stage. We found an aver-
age lethality rate of 23.8% in adult VEGFECKO mice with
a peak between 20 and 25 weeks (Figure 1E and Table
S2). Additional crosses (between VE-CAD-Cre/VEGF+/+,
VE-CAD-Cre/VEGFlox/+, and VEGFECKO) and genotype
analyses of the resulting mice at 4 weeks showed consis-
tent small size litters for VEGFECKO crosses (Figure 1F)
and stressed the contribution of endothelial VEGF to vas-
cular development.
VEGFECKO that survived into the adulthood were indis-
tinguishable from control littermates. VEGFECKO mice692 Cell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc.between 8 and 24 weeks did not show any external path-
ological manifestations that could aid in predicting sudden
death. After 30 weeks, however, VEGFECKO mice fre-
quently exhibited signs of fatigue and waste and became
lethargic.
Systemic Vascular Pathologies in VEGFECKO Mice
Evaluation of VEGFECKO mice and littermate controls be-
tween 40 and 50 weeks of age revealed organ failure
associated with systemic vascular pathologies. Hemor-
rhages (Figures 2Ag, 2Ai, and 2Al), intestinal perforations
(Figure S1Bg), and signs of multiple microinfarcts were
frequently noted in older mice after macroscopic inspec-
tion (Figure 2Aj). In addition, older mice exhibited occa-
sional neointimal hyperplasia and frequent disruption in
the elastic lamina of larger vessels (Figure S1A).
To gain further insight into the defects that preceded
these outcomes, histological analysis was performed in
mice between 8 and 20 weeks, a time when no external
differences were noted between control and VEGFECKO
mice (Figure 2B). Evaluation of lungs from VEGFECKO
showed a chronic inflammatory state even in young
mice (Figure 2Bb), endothelial cell rupture (Figure 2Bc),
vascular constriction (Figure 2Bc), and significant fibrosis
(Figure 2Bd). Fibrinogen accumulation was found in sev-
eral organs including lung (Figure 2Be), uterus
(Figure 2Bj), ovary (Figure 2Bo), spleen (Figure 2Bt), and
bone marrow (Figure 2By). In addition, hemosiderin de-
posits were detected in most organs examined (Figures
2Bh, 2Bi, 2Bm, 2Bn, 2Br, 2Bs, 2Bw, and 2Bx), indicating
the previous occurrence of hemorrhagic events. To-
gether, these results indicate that endothelial VEGF is re-
quired for the systemic stability of the vasculature. These
defects occurred in the absence of alterations in VEGFR2
protein levels, as confirmed by western blot analysis
(Figure 2C).
Systemic Endothelial Apoptosis in VEGFECKO Mice
We postulated that endothelial apoptosis in VEGFECKO
mice could be a possible cause of the multiple hemor-
rhagic and thrombotic events. Indeed, endothelial cells
positive for cleaved caspase-3 were frequently observed
in VEGFECKO and the percentage increased with age
(Figure 3A); this was in sharp contrast to control litter-
mates (data not shown). Ultrastructural examination of en-
dothelial cells in VEGFECKO also revealed typical morpho-
logical changes associated with apoptotic cell death.
These included membrane blebbing (Figure 3Bb), cell
shrinkage (Figure 3Bc), cell rupture (Figure 3Bd), nuclear
condensation (Figure 3Bd), and exposure of cytosolic
components (Figure 3Bd). Since apoptotic endothelial
cells are procoagulant (Blann, 2003; Choy et al., 2001),
these results explain the development of thromboembo-
litic events and cardiac ischemic episodes (platelet adhe-
sion, thrombi, accumulation of von-Willebrand’s Factor
[vWF], and fibrinogen deposits) that resulted in the sudden
death of a cohort of animals.
Figure 1. VEGF Expression by Endothelial Cells and Generation of VEGFECKO Mice
(A) Expression of LacZ reporter (blue) driven by the vegf promoter in nonpathological adult tissues. Note promoter activity in endothelial cells (arrows).
In larger vessels, positive (arrows) and negative (arrowhead) endothelial cells are observed.
(B) (Top) Schematic diagram of the transgenicmice used to generate VEGFECKOmice. (Bottom) Genotyping of tail DNA. A band of 850 bp indicates the
presence of the Cre transgene. Only animals from lanes 2 and 4 harbored the Cre-recombinase transgene (left). A 100 bp band indicates wild-type (wt)
allele and the 150 bp corresponds to the vegf lox allele (right).
(C) Endothelial cells isolated from Cre+/Rosa+/VEGFlox/lox (VEGFECKO) and Cre-/Rosa+/VEGFlox/lox mice stained for b-gal. Arrows point to endothelial
cells expressing Cre and arrowheads to cells with no Cre expression (approximately 95% of the isolated cells were positive).
(D) Survival analysis. Mortality rate of newborn VEGFECKO at P0 was calculated by predicted mendelian distribution and expected litter size. Survival
rate of VEGFECKO at six months was 44.7%.
(E) Mortality of adult cohorts.
(F) Litter size variability. VEGF+/+3 VEGF+/+, 6 ± 1.33 (n = 10); VEGFlox/+3 VEGFlox/+, 7.15 ± 1.76 (n = 20); VEGFECKO3 VEGFECKO, 4.0 ± 1.30 (n = 11).Microinfarctions and Intravascular Thrombosis
in the Coronary Vessels of VEGFECKO Mice
Prior to 24 weeks, a proportion of VEGFECKO mice experi-
enced sudden death. Therefore, we suspected cardiac
pathology or stroke. Macroscopic analysis of the heart
from adult VEGFECKO showed possible signs of multiple
microinfarctions, revealed as accumulated fibrotic areas
(Figure 2Aj) that were not found in littermate controls
(Figure 2Ad). Myocardial infarction (MI) results from the
rapid development of cellular necrosis caused by a critical
imbalance between the oxygen supply and demand of the
myocardium. The most common cause of MI is narrowing
of the epicardial blood vessels due to atheromatous pla-
ques. Plaque rupture with subsequent exposure of the
basement membrane results in thrombus formation, pla-
que development, and acute reduction of blood supply
to a portion of the myocardium (van Gaal et al., 2006). His-
tological evaluation of heart sections from VEGFECKO andcontrol littermates revealed the presence of intravascular
thrombi (Figure 4Ab, asterisks), platelet adhesion to the
endothelial wall (Figure 4Ad, arrows), and disrupted endo-
thelial lining (Figure 4Ac, arrows) but the absence of any
sign of atherosclerosis. Accumulation of both vWF (Fig-
ures 4Ae–4Ah) and fibrinogen (Figures 4Ai–4Al) was also
found by immunocytochemistry. The thrombotic pheno-
type was noted in most animals and its frequency in-
creased with age. Together, these results indicate that en-
dothelial-derived VEGF is essential to the regulation of the
antithrombotic properties of the vessel wall.
To further explore the relationship between the cardiac
phenotype and the nature of the cellular insults imposed
on the endothelium, tissue sections were examined after
immunostaining with a pan-endothelial marker. PECAM
staining of hearts from VEGFECKO showed ruptured
and discontinued endothelial lining (Figures 4Am–4Ap,
arrows).Cell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc. 693
Figure 2. Systemic Vascular Pathologies
in VEGFECKO Mice
(A) Macroscopic analyses. a–f: Control. g–l:
VEGFECKO. VEGFECKO organs of older mice
(40–50 weeks old) show hemorrhage (arrows
in g, i, and l), tortuous and dilated vessels (ar-
rows in h), areas of suggestive collagen accu-
mulation in the heart indicative of microinfarcts
(arrows in j), and intestinal perforations (arrows
in k) (also see histology in Figure S1).
(B) Histological sections of organs from youn-
ger mice (8–20 weeks old). a–e: lung. Lung in
VEGFECKO mice shows chronic inflammation
(b), fibrosis (d), and excess of intravascular fi-
brin(ogen) deposits (e). PECAM staining re-
veals ruptured endothelial cells (arrowhead, c)
and collapsed lumen (arrow, c). f–j: uterus.
k–o: ovary. VEGFECKO ovary shows signifi-
cantly enlarged vessels surrounding mature
follicles (l) compared to wild-type ovary (k).
p–t: spleen. Asterisk in (s) indicates fibrosis.
u–y: bone marrow. Fibrin(ogen) staining re-
veals clotting from VEGFECKO organs (arrows,
e, j, o, t, and y). Hemosiderin deposits were in-
dicated by arrows in (h), (i), (m), (n), (r), (s), (w),
and (x). Bar, 100 mm.
(C) VEGFR2 protein levels from control and
VEGFECKO at 25weekswere determined by im-
munoblots (same amount of protein was
loaded per well). Slight differences in the uterus
correlate with estrous cycle.The intravascular thrombotic phenotypemay also relate
to alterations in the hematopoietic compartment. Indeed,
VEGF has been shown to regulate hematopoietic progen-
itors (Gerber et al., 2002), and unfortunately, the constitu-
tive VE-CAD-Cre model is penetrant in approximately
60% of all hematopoietic lineages (Alva et al., 2006). To
ascertain whether vegf deletion from bone marrow cells
contributed to the observed phenotype, we examined
the constituency of circulating and bone marrow cells by
flow cytometry (Figure S2). No significant differences
were noted in blood counts (Figures S2A and S2B) or in
the frequency of myeloid (Gr-1/Mac-1), erythroid (Ter-
119/CD71), megakaryocytic (CD71/CD41), and B cell
(B220) lineages between control littermates and VEG-
FECKO mice (Figures S2C and S2D). Surprisingly, we also
failed to detect differences in apoptosis in bone marrow
cells and lineage constituency in LacZ+ cells between
control and VEGFECKO (Figure S3). To further ascertain
the possible contribution of bone marrow cells in the694 Cell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc.thrombotic phenotype, we performed a series of bone
marrow transplantation experiments in which VEGFECKO
bone marrow cells were introduced into lethally irradiated
control mice, and vice versa. Both recipient mice survived
and showed equivalent levels of bone marrow incorpora-
tion (Figure S4). However, only VEGFECKO recipients of
control bone marrow developed vascular rupture, intra-
vascular thrombosis, and hemorrhagic events (Figure S5);
in contrast, control recipients of VEGFECKOmarrow did not
develop vascular pathology. Combined, these results
suggest that the phenotype observed was endothelial
cell specific and cell autonomous.
VEGFECKO Mice Have Significant Cardiac
Dysfunction
To further investigate the relationship between cellular ab-
normalities in VEGFECKO mice and the sudden-death phe-
notype, we examined several aspects of cardiac physiol-
ogy. Control and VEGFECKO male mice (n = 11 each) were
first evaluated for left ventricular dimensions and contrac-
tile function via echocardiography. The VEGFECKO dem-
onstrated lower contractile function in comparison to their
control littermates. As shown in Figure 4B, their ejection
fraction was reduced by 19%, while other indices of
ventricular performance showed similar dysfunction;
fractional shortening dropped from 37.4% ± 1.3% to
28.8% ± 1.5% (p < 0.001; control versus VEGFECKO,mean ±
SEM) and the velocity of circumferential fiber shortening
(Vcf) was reduced from 6.28 ± 0.28 to 4.59 ± 0.26
Figure 3. Evidence of Endothelial Cell Apoptosis in VEGFECKO
Mice
(A) Endothelial expression of cleaved caspase-3 in VEGFECKO mice.
Representative sections double-stained for PECAM (green) and
cleaved caspase-3 (red) are shown. Arrows point to vessels with active
caspase-3. Arrowheads indicate caspase-3-negative vessels. Bar,
100 mm.
(B) Electronmicroscopic evidence of endothelial cell apoptosis in heart
sections. Endothelial cells of VEGFECKO heart (b–d) show morpholog-
ical characteristics of apoptotic cells, including cytoplasmic swelling
(b, arrow), cell constriction (c, arrow), nuclear condensation (d, arrow),
and the exposure of cytosolic components (d, asterisk). Also note
mitochondria swelling in (d) (arrowhead). Bar, 3.5 mm.(lengths/s) (p < 0.001). VEGFECKO hearts were dilated with
greater end diastolic dimensions (EDD: 4.07 ± 0.08 mm
to 4.37 ± 0.06 mm, control versus VEGFECKO) and end
systolic dimensions (ESD: 2.55 ± 0.09 to 3.12 ± 0.1 mm;
p < 0.001) without changes in wall thickness.
With evidence for ventricular dysfunction and vascular
clots, the electrocardiograms (ECG), body temperatures,
and cage activity were evaluated via telemetry in awake,
free-roaming male mice (n = 3 each) and one female
VEGFECKO mouse. There were no significant differences
in cage activity or body temperature between the groups
at the same time during the day. All control mice showed
normal mouse waveforms exhibiting P, QRS, Tri, and T
waves (Figure 4C, top waveforms). In contrast, VEGFECKO
mice displayed abnormal ECG waveforms (Figure 4C,
lower traces) mixed in with relatively normal waveforms.
Abnormal waveforms could have P waves going either
positive or negative, large negative R waves, minimal or
missing Tri waves, and normal T waves. Though the PR
and QT intervals were normal in both groups, the QRS du-
ration increased from 12ms in control mice to 16–22ms in
the abnormal QRS complexes of the VEGFECKO. Two of
the VEGFECKO mice had abnormal waveforms over 25%
of the time during the 4 months of the recording period
while the other two had fewer episodes (1%–2% range).
Interestingly, the frequency of abnormal waves increased
as the mice became aged.
Heart rates were lower in VEGFECKO as compared to
control mice. Figure S6A (baseline) shows the difference
during the light (resting) circadian cycle. During the dark
(active) cycle, heart rates increased in both groups but re-
mained lower in the VEGFECKO (584 ± 15 versus 537 ± 1 0,
control versus VEGFECKO, p < 0.05). Additionally, the coef-
ficient of variance in heart rate (%CV) was significantly
(p < 0.001) greater in the VEGFECKO, indicating more var-
iability in the heart rate (Figure 4D). Such variability can
be seen in the abnormal VEGFECKO mouse waveform
(Figure 4C, bottom, left-right arrows). We also exposed
mice to exercise-induced stress and found that the
VEGFECKO group performed more poorly than controls
(Figures S6A and S6B).
Because of the variation in heart rate, we examine
whether Cre-mediated deletion affected the cardiac con-
duction system. X-gal staining in Purkinje fibers (identified
by Periodic Acid Schiff [PAS]) demonstrated that Cre ac-
tivity was confined to the endothelial component of the
heart (Figure S7).
Autocrine VEGF Signaling Promotes
Endothelial Survival
Further mechanistic analysis of the VEGFECKO phenotype
required a detailed systemic assessment of VEGF. Levels
of VEGF in plasma and serum were indistinguishable be-
tween control and VEGFECKO mice (Figure 5A). Further-
more, evaluation of VEGF transcripts in whole organs by
real-time RT-PCR showed no differences between the
groups except for the lung, where VEGFECKO had a statis-
tically significant increase, likely due to the chronicCell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc. 695
Figure 4. Intravascular Thrombosis in
VEGFECKO Mice Affects Cardiac Physiol-
ogy
(A) a–d: Gomori trichrome staining. Frequent
intravascular thrombi (b, asterisks), detach-
ment of endothelial lining (c, arrow), and plate-
let adhesion (d, arrows) in VEGFECKO hearts are
shown. e–h: von-Willebrand Factor (vWF)
staining shows accumulation in the vascular
wall of mutant mice (arrows). i–l: Fibrinogen
staining was also increased (arrows). m–p:
PECAM staining shows detachment of endo-
thelial cells (n, o, arrows) and collapse of
vascular wall (p, arrows). Bars: a–c, f, g, i–k,
and m = 35 mm; d, e, h, l, n, o, and p = 10 mm.
(B) VEGFECKO mice (green) have reduced ejec-
tion fraction compared to control littermates
(blue) (means ± SD, n = 11 ea, *p < 0.001).
(C) ECG traces obtained from control (top) and
VEGFECKO (bottom) mice. The left-right arrows
in VEGFECKO indicate the variability in heart
rate and amplitude. Time bar = 0.5 s. The right
panels show expanded ECG traces with the
defections annotated. Time bar = 0.5 s.
(D) Increased heart rate variability from control
(blue) to VEGFECKO (green) during both diurnal
cycles (mean ± SD, n = 3 ea, *p < 0.001).inflammatory state (Figure 5B). These findings indicate
that endothelial VEGF is not a major source of circulating
or total VEGF levels in tissues and that the systemic endo-
thelial dysfunction of VEGFECKO was not rescued by unal-
tered levels of paracrine VEGF. Additional comparisons
between control and VEGFECKO showed equivalent capil-
lary density (Figure 5C), angiogenic response in matrigel
plugs (Figure 5D), frequency of endothelial fenestrations
(Figures 5E and 5F), and vascular permeability (Figure 5G).
To gain further insight into the cell-autonomous func-
tions of VEGF, we isolated endothelial cells from control
and VEGFECKO mice. After several isolations, it became
clear that the VEGFECKO endothelium either proliferated
with slower kinetics or died more frequently. While this
was more evident after a week in culture, the difference
was statistically significant as early as 72 hr post-culture
(Figure 6A). Stress, such as serum starvation, exacerbated
differences between control and VEGFECKO endothelial
cells (Figure 6B). Consistent with the findings in vivo
(Figure 3A), assessment of active caspase levels upon ex-
posure to CoCl2 (to simulate hypoxia) showed a four-fold
increase in VEGFECKO endothelial cells in comparison to
control (Figure 6C). This was correlated with a significant
difference in endothelial cell survival (Figure 6D). Further-
more, addition of exogenous VEGF did not rescue for696 Cell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc.the increased cell death exhibited by VEGFECKO endothe-
lial cells (Figure 6D). These findings uncovered an impor-
tant role for autocrine VEGF signaling in survival mecha-
nisms following hypoxia-mediated stress for which
paracrine sources of VEGF cannot compensate.
If these findings are correct, one should be able to de-
tect activation of VEGF receptors in the absence of exog-
enous VEGF. Indeed, phosphorylation of VEGFR2 was
consistently found in human endothelial cells (Figure 6E).
Levels of VEGFR2 phosphorylation significantly increased
when the cells were exposed to CoCl2 (Figure 6E). To as-
sess whether hypoxia triggered VEGF increase, endothe-
lial cells were treated with CoCl2 and the levels of VEGF
transcripts were measured by real-time RT-PCR. Control
endothelial cells upregulated VEGF transcripts by 5.3-
fold under hypoxia, whereas VEGFECKO endothelial cells
showed only minimal induction (Figure 6F) (consistent
with the 95% endothelial VEGF excision previously
shown; Figure 1C). Notably, under normoxia, wild-type
endothelial cells had 6.4 times more vegf transcripts
than VEGFECKO endothelial cells, which further confirms
expression of VEGF by endothelial cells and its upregula-
tion following hypoxic stress (Figure 6F). Interestingly, the
same VEGFECKO endothelial cells were able to respond to
hypoxia by increasing GAPDH expression to levels similar
Figure 5. VEGF Levels, Vessel Density,
Endothelial Fenestrations, and Vessel
Permeability Are Unaltered in VEGFECKO
(A) Serum VEGF levels from control (blue) and
VEGFECKO (green) mice were determined by
ELISA.
(B) Organs from control and VEGFECKO were
analyzed for vegf (left) and gapdh (right) tran-
scripts by real-time RT-PCR. Relative RNA
units (RRU) were normalized to b-actin levels
and calculated from standard curves.
(C) Assessment of vascular density. Data
shown are means (n = 4) ± SD (left). Represen-
tative PECAM-stained sections of uterus are
shown on the right.
(D) Induction of angiogenesis in control and
VEGFECKO using Matrigel plugs containing
VEGF. Arrows indicate neovessels invading
the Matrigel plug.
(E) Ultrastructural analyses of glomerular capil-
laries. Arrows show fenestrations in control
and VEGFECKO mice. Note the swelling of
VEGFECKOendothelium (asterisk in d and closed
triangle in f), yet these cells still retain fenestra-
tions (arrows).
(F) Quantification of fenestrations in control
and VEGFECKO mice. Glomerular fenestrations
from control and VEGFECKO were determined
using ultrastructural information obtained
from four mice. Data shown are means ± SD.
The difference is statistically insignificant
(p > 0.1).
(G) Vascular permeability responses. (Left)
Photographs of control and VEGFECKOmice in-
jected with Evans blue followed by application
of vehicle or mustard oil (arrow) in the ear.
(Right) Quantification of extravasated Evans
blue dye from control and VEGFECKO. Data
are presented as ratio to uninjected ear.
p value was not significant (p > 0.1).to control (Figure 6G), indicating that these cells were not
only viable but also fully capable of responding to hypoxic
stress.
To ascertain whether the effect of VEGF was paracrine
(i.e., secreted and acting in adjacent cells) or autocrine, we
performed individual and coculture experiments with con-
trol and VEGFECKO endothelial cells. Under both situa-
tions, VEGFECKO endothelial cells displayed a greater
degree of cell death (Figures 6H and 6I). These findings
demonstrate that the effect of VEGF was indeed cell
autonomous, as control cells were not able to rescue
VEGFECKO endothelial cells.
Further exploration of the autocrine VEGF signaling
pathway was performed with extracellular inhibitors of
VEGF (Avastin) and intracellular suppressors of VEGFR2
activation (SU4312). In the absence of exogenous VEGF,
Avastin failed to block phosphorylation of VEGFR2,
whereas SU4312 substantially neutralized the activity of
endogenous VEGF by blocking VEGFR2 phosphorylation
(Figure 7A). These results indicate that the phosphoryla-tion of VEGFR2 is likely to occur intracellularly and in the
absence of VEGF secretion. Controls for both Avastin
(Figure 7B) and SU4312 (Figure 7C) were shown to block
VEGFR2 phosphorylation mediated by exogenous
VEGF. The possibility of VEGFR2 autophosphorylation in
the absence of VEGFwas ruled out by evaluation of recep-
tor activation in endothelial cells from VEGFECKO mice. In
these cells, exogenous VEGF elicited significant VEGFR2
phosphorylation, whereas no phosphorylation was ob-
served in the absence of exogenous growth factor
(Figure 7D). Finally, intracellular but not extracellular sup-
pression of VEGFR2 was cytotoxic, as HUVECs cultured
in the presence of SU4312 were unable to survive under
serum-free conditions (Figure 7E).
DISCUSSION
While the contribution of VEGF to the induction of vascular
growth has long been accepted, our data indicate that the
function of this growth factor expands its classical effectCell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc. 697
Figure 6. Endothelial VEGF Mediates Survival in a Cell-Autonomous Manner
(A and B) Endothelial cells from control (blue) and VEGFECKO (green) mice were cultured in the presence (A) or absence (B) of serum and viable cells
were counted at indicated times. Endothelial cells were stained with X-gal and nuclear fast red (right panels, B). Note the differences in cell number
between control and VEGFECKO cells. *p < 0.001.
(C) Endothelial cells from control and VEGFECKOwere cultured in the presence of CoCl2; active caspases were fluorescence-labeled and quantified by
fluorometer.
(D) Endothelial cells from control and VEGFECKO were cultured in the presence of recombinant hVEGF165 or CoCl2 and viable cells assessed after
48 hr. *p < 0.001.
(E) HUVECs were cultured under hypoxia for 24 hr and analyzed for VEGFR2 phosphorylation (pVEGFR2, top) and VEGFR2 total levels (bottom).
Lanes: 1, VEGF (100 ng/ml) for 5 min; 2–3, normoxia in the presence (2) and absence (3) of sodium orthovanadate (Na3VO4, to inhibit phosphatases)
for 24 hr; 4–5, CoCl2 (hypoxia mimetic) in the presence of Na3VO4 for 24 hr.
(F and G) Endothelial cells from control and VEGFECKO were cultured in the presence of CoCl2 (100 mM) for 24 hr, and transcript levels of vegf (F) and
gapdh (G) were determined by real-time RT-PCR. Relative RNA units (RRU) were normalized to b-actin. Data shown are means ± SD, *p < 0.001.
(H) Endothelial cells differentially labeled (Cy3 for wild-type and BODIFY green for VEGFECKO) were cultured alone (left) or combined (right). Photo-
graphs were taken after 2 days and 5 days. Arrows indicate control cells (red). Arrowhead points to VEGFECKO cells (green).
(I) Quantification of cell survival following coculture. Fluorescence labeled cells were counted at indicated times. Data are presented as percentage to
control.as the main mediator of developmental and pathological
angiogenesis. Here we show that in vivo autocrine VEGF
signaling is required for endothelial cell survival under non-
pathological conditions in a cell-autonomous manner.
One of the surprises revealed by these experiments was
that removal of endothelial VEGF could not be sufficiently
compensated for by VEGF secreted from adjacent cell
types. Evaluation of circulating VEGF protein and tran-
scripts levels from several organs did not show any signi-
ficant difference between control and VEGFECKO mice,
indicating that endothelial VEGF does not sum up to698 Cell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc.a detectable proportion of the total growth factor present
in any given organ. Interestingly, while endothelial VEGF
constitutes a minor proportion of the total VEGF, it holds
high functional significance. A second important conclu-
sion drawn from our studies is that autocrine VEGF does
not contribute to the angiogenic response, as vascular
density and patterning were virtually identical between
control and VEGFECKO mice. Clearly, the majority of the
experimental data published so far support the notion
that the progression of angiogenesis requires exogenous
presentation of VEGF. Indeed, removal of VEGF from cells
Figure 7. Autocrine VEGF Signaling in Endothelial Cells
(A) HUVECs were cultured under normoxia for 24 hr and in the presence of the indicated compounds and analyzed for VEGFR2 phosphorylation (top)
and VEGFR2 total levels (bottom). Lanes: 1, 100 ng/ml VEGF for 5 min; 2, media; 3, Na3VO4; 4 and 5, Avastin (10 mg/ml, 4) or SU4312 (0.4 mM, 5) in the
presence of Na3VO4.
(B) HUVECs were exposed to VEGF (100 ng/ml, preincubated with Avastin at 37C for 2 hr) for 5 min. Phosphorylation of VEGFR2 (top) and VEGFR2
(bottom) are shown. Lanes: 1, VEGF; 2, media; 3–6, VEGF preincubated with 1 ug/ml Avastin (3), 5 ug/ml Avastin (4), 10 ug/ml Avastin (5), and
100 ug/ml Avastin (6); 7, Avastin (1 ug/ml).
(C) HUVECs incubated with VEGF (100 ng/ml, lane 1) or vehicle (lane 2). In lane 3, HUVECs were preincubated with SU4312 at 37C for 2 hr and then
exposed to VEGF (100 ng/ml). Phosphorylation of VEGFR2 (top) and total levels of VEGFR2 (bottom) are shown.
(D) Endothelial cells from VEGFECKO were cultured under normoxia for 24 hr and subjected to the indicated treatments. Lysates were analyzed
for VEGFR2 phosphorylation. Lanes: 1, VEGF (100 ng/ml) for 5 min; 2, media; 3, Na3VO4; 4 and 5, Avastin (10 mg/ml, 4) or SU4312 (0.4 mM, 5) in
the presence of Na3VO4.
(E) HUVECs were cultured in the absence of serum with indicated VEGF or VEGF signaling blockers. Values represent ration to control (Media) ± SD.
(F) Model illustrating the contribution of VEGF to endothelial homeostasis. Local stress induced by radiation, reactive-oxygen species, and/or hypoxia
triggers survival signals on endothelial cells (black cells, wild-type). Some of these signals are mediated by activation of VEGFR2 supporting endo-
thelial survival. In the absence of auto-/intracrine VEGF, paracrine sources of the growth factor are not sufficient to support survival of all affected
cells, and some endothelial cells undergo apoptosis resulting in hemorrhage and/or exposure of the underlying basement membrane (black cells,
VEGFECKO) with subsequent development of thrombi (red cells, VEGFECKO). In the bottom, the scheme shows an endothelial cell in which paracrine
and auto-/intracrine activation result in differential endothelial responses, as indicated.other than endothelial has repeatedly resulted in the
reduction of vascular growth (Gerber et al., 1999), a phe-
notype that is not shared by the VEGFECKO mice. Also,
reduction in size or developmental retardation as
a consequence of general VEGF decrease was never
noted in VEGFECKO. The nature of the defects in our model
appears to be restricted to endothelial viability. Together
these findings indicate that cell-autonomous signaling
triggers a response that does not fully overlap with theevents initiated by paracrine activation. Thus, paracrine
VEGF signaling is essential for the angiogenic cascade,
proliferation, survival, permeability responses, and endo-
thelial differentiation. In contrast, autocrine VEGF signal-
ing only conveys survival signals (Figure 7F). Interestingly,
both paracrine and autocrine activation are mediated by
the main initiating receptor (VEGFR2). It should be
stressed that our data do not exclude paracrine VEGF sig-
naling in survival functions. Instead, our findings indicateCell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc. 699
that provision of survival signals in a paracrine mode alone
is insufficient.
The concept of an autocrine signaling loop for VEGF has
been previously shown in bone marrow endothelial cell
progenitors (Gerber et al., 2002). The experiments here
would indicate that the functional significance of cell-
autonomous signaling is broader than anticipated and it
impacts fully differentiated, normal endothelial cells as
part of a homeostatic program. Thus, we propose amodel
in which survival signals are required to support viability of
the endothelium. These survival signals are likely triggered
by stress situations, such as irradiation, hypoxia, and re-
active oxygen species. Activation of VEGFR2 by endoge-
nous VEGF sources enables endothelial survival (Fig-
ure 7A). While there is much to be understood, as to the
regulation of endothelial VEGF in vivo, our findings would
indicate that long-term ablation of VEGF signaling within
the endothelial compartment or direct blockade of
VEGFR2 might have a deleterious systemic impact in the
vasculature of normal tissues.
VEGF is an integral component of tumor angiogenesis,
and its inhibition results in reduction of tumor burden sub-
sequent to the regression of some tumor vessels and im-
proved drug delivery (Inai et al., 2004; Jain, 2001). Conse-
quently, many therapeutic strategies for agents that block
VEGF signaling either by neutralizing VEGF or by inhibiting
its receptors have been pursued. Some of these agents
have shown promise in clinical trials (Hurwitz et al.,
2004; Willett et al., 2004). However, although reduction
in tumor burden and survival benefit has been demon-
strated, some side effects were also noted, including hy-
pertension and thromboembolism. Other pathologies,
while not as consistent, include hemorrhage, proteinuria,
intestinal perforations, and congestive heart failure (Jain
et al., 2006; Kabbinavar et al., 2003). Such findings indi-
cate that VEGFparticipates in a number of functionswithin
normal tissues that exceed its role as proangiogenic
agent. The contribution of VEGF in the regulation of blood
pressure remains enigmatic. Deletion of vegf from the en-
dothelium does not result in hypertension or changes in
eNOS levels/activation (data not shown), nor did we ob-
serve proteinuria, at least prior to 30 weeks of age (data
not shown). However, VEGFECKO showed hemorrhage,
thrombosis, and intestinal perforations; we attribute
most of these side effects to a long-term interruption in
VEGF-mediated survival in an autocrine manner. While
the consequence of long-term pharmacological ablation
(or reduction) of VEGF signaling is not really known, our
data would indicate that the homeostatic function of the
VEGF-VEGFR2 within the endothelial compartment is of
considerable biological significance.
Evaluation of signaling by endogenous VEGF in vitro
suggests that activation of VEGFR2 might occur intracel-
lularly. The experimental evidence for this conclusion is
that blockade with Avastin did not affect the degree of
VEGFR2 phosphorylation, unlike the effect mediated by
a small molecular inhibitor of VEGFR2 that can enter the
cell freely and completely suppress activation of the700 Cell 130, 691–703, August 24, 2007 ª2007 Elsevier Inc.receptor. In addition,we found that control endothelial cells
are unable to rescue VEGFECKO endothelial cells in cocul-
ture experiments. Previous examples of intracrine signal-
ing have been presented in the literature. For example,
the amino-terminal propeptide of type I collagen inhibits
BMP2-mediated osteoblast differentiation by triggering
activation of a putative intracellular receptor in the secre-
tory pathway (Oganesian et al., 2006). Intracrine activation
of receptor tyrosine kinases have been predicted for
PDGF and TGF-beta (Betsholtz et al., 1984; Sporn and To-
daro, 1980), and the concept that ligand-receptor binding
complexes are internalized to signal only in an endosomal
compartment has been long demonstrated for EGF (Co-
hen and Fava, 1985). More recently, endosomes were im-
plicated in the maintenance of Dpp signaling during mito-
sis and in the even distribution of signaling bodies to
daughter cells (Bokel et al., 2006). It is also becoming ap-
parent that internalized cell-surface receptors might use
specifically localized complexes to initiate signals that
are distinct from those triggered at the cell surface (Child-
ress et al., 2006; Seto and Bellen, 2006). In this manner,
compartmentalization of signaling could regulate signal
transduction spatially and temporally (van der Goot and
Gruenberg, 2006). This would ultimately assign unique bi-
ological responses through the same ligand-receptor
complex. While we have yet to explore compartmentaliza-
tion of VEGF signaling, it has been recently shown that in-
ternalized VEGF receptors can signal from endosomes in
a manner that is regulated by VE-Cadherin (Lampugnani
et al., 2006).
In conclusion, the studies communicated here reveal
a previously unknown function for VEGF in vascular ho-
meostasis in vivo. They also indicate that cell-autonomous
VEGF signaling is likely triggered inside the cell. These sig-
naling events differ from those initiated by exogenous/




VEGF-LacZ mice (Miquerol et al., 1999), VE-CAD-Cre transgenic mice
(Alva et al., 2006), and floxed-VEGF mice were previously described
(Gerber et al., 1999).
Histological Analysis
Tissues were fixed in 4% paraformaldehyde, paraffin-embedded, and
sectioned at 5 mm. For immunohistochemistry we used the following:
rat anti-mouse PECAM (BD Biosciences PharMingen, CA), rabbit
anti-mouse fibrinogen (Chemicon, CA), rabbit anti-mouse vWF (BD
Biosciences PharMingen), and secondary antibodies purchased
from Vector laboratories (CA). For X-gal staining, tissues were sec-
tioned on a vibratome (Ted Pella, CA) at 400 m prior to staining as pre-
viously described (Alva et al., 2006). For electronmicroscopic analysis,
tissues were fixed in 2% paraformaldehyde, 2% glutaldehyde in
50mMsodiumcacodylate buffer. Sectionsweremounted on inert grids
and stained by the Microscopic Techniques and Electron Microscopy
Core facility at UCLA. For the evaluation of apoptosis, organs were
fixed in 1% paraformaldehyde, sectioned at 400 mm, and double-
stained with rat anti-mouse PECAM (to visualize vessels) followed by
FITC-labeled goat anti-rat IgG antibody (Jackson ImmunoResearch
Laboratories, PA) and with rabbit anti-Cleaved Caspase-3 (Cell Signal-
ing Technology, MA) followed by Cy3-secondary antibody (Jackson
ImmunoResearch Laboratories, PA).
Echocardiography
Mice were anesthesized with isoflurane vaporized in oxygen (2.5% in-
duction, 1.0%maintenance) and ultrasonically imaged with a Siemens
Acuson Sequoia C256 (Siemens Medical Solutions, PA) as previously
described (Jordan et al., 2005). Two-dimensional, M-mode, and spec-
tral Doppler images were acquired to obtain measures of left ventricu-
lar size, mass, wall thickness, and ventricular function using the
Acuson and AccessPoint software (Freeland Systems, LLC, NM).
Ambulatory Monitoring of Cardiac Function by Telemetry
Radio telemetry devices (TA10ETA-F20; Transoma-Data Sciences
Intl., MN) were implanted as previously described (Jordan et al.,
2005). Unfiltered ECG waveforms, body temperature, and bioactivity
data were collected for 30 s every 10 min for 4 months. Data wave-
forms and parameters were analyzed with the Data Sciences analysis
packages (ART 3.01 & Physiostat 4.01). The coefficient of variance
(%CV), an index of heart rate variability, was determined from sequen-
tial R-R intervals.
Statistical Methods
Data were evaluated using a Student’s two-tailed t test or ANOVA with
Instat V3.05 statistical software (GraphPad Inc., CA). p < 0.05 was
taken to be statistically significant.
Matrigel Assays
Mice were injected with 250 ml of growth factor-reduced Matrigel (BD
Biosciences) that was supplemented with VEGF (1 mg). Matrigel plugs
were harvested and evaluated for b-galactosidase activity. Specimens
were subsequently fixed with 4% paraformaldehyde in PBS, embed-
ded in paraffin, and stained with nuclear fast red.
Vascular Permeability Assays
Evans blue dye (1 ml/kg of 3% Evans blue) was injected into the tail
vein of 15- to 16-week-old mice. Mustard oil (Allylisothiocyanate,
Fluka, Germany) diluted to 5% in mineral oil was applied to the dorsal
surfaces of the ear with a cotton swab after injection of Evans blue.
Photographs were taken 15 min after stimulus and the vasculature
was perfusion-fixed (1% paraformaldehyde in 50 mM citrate buffer,
pH 3.5) for 2 min. Ears were removed, blotted dry, and weighed. Evans
blue was extracted from the ears with 1 ml of formamide overnight at
55C and measured by spectrometer at 610 nm.
Total RNA Isolation and Real-Time RT-PCR Analysis
Total RNA was isolated on RNeasy Quick spin columns (QIAGEN, CA).
0.3–0.4 mg of total RNA per reaction were analyzed using the TaqMan
RT-PCR kit from Applied Biosystems (NJ), following the manufac-
turer’s instructions. Reactions were run in 96-well plates in a DNA En-
gine OpticonII System from Bio-Rad (Hercules, CA), and results were
analyzed using built-in software. Probe primer sequences for murine
vegf are 50-TGTACCTCCACCATGCCAAGT-30 and 50-CGCTGGTAGA
CGTCCATGAA-30. gapdh sequences are 50-CATGTTTGTGATGGG
TGTGA-30 and 50-AATGCCAAAGTTGTCATGGA-30. Expression levels
were standardized to the probe/primer sets specific for b-actin: 50-
TCAAGATCATTGCTCCTCCTGAGC-30 and 50-TACTCCTGCTTGCT
GATCCACATC-30. Primers were purchased from IDT (Coralville, IA).
Quantification of Capillary Density and Fenestration
Endothelial fenestrations in control and VEGFECKO mice were counted
using electron micrograph images of endothelial cells from the kidney.
Quantification was determined in 7–12 capillaries using two indepen-
dent specimens for control and three for VEGFECKO. Fenestrations
were identified as gaps of 50–100 nm in diameter. Capillary density
was determined using micrograph images of PECAM immunochemi-cally stained endothelial cells from six organs. Quantification was
made using 4 animals for both control and VEGFECKO, 3–5 indepen-
dent specimens.
Isolation of Liver Endothelial Cells from Mouse
Mice were perfused with serum-free DMEM (Mediatech, Inc., VA) and
collagenase (500 mg/ml, Sigma, MO). Livers were harvested and incu-
bated in collagenase (500 mg/ml) for another 15 min. Supernatants
were mixed with equal volume of DMEM containing 20% FBS. Cells
were collected after centrifugation at 2000 rpm for 5 min, resus-
pended, and filtered through a 40 mm pore size top filter (BD, NJ). Fil-
tered cells were plated onto gelatin-coated tissue culture dishes and
washed after 2–3 hr to remove cell debris and remaining blood cells.
Examination of Endothelial Cell Growth and Apoptosis
Toassess the cell growth, endothelial cells (5000cells/well) were plated
onto gelatin-coated 96-well plates and the viable cell number was de-
termined using cell counting kit-8 (CCK-8 kit, Dojindo Molecular Tech-
nologies, Inc., MD). Active caspase levels were determined with APO
LOGIX (Cell technology Inc., CA). To chemically simulate hypoxia, cells
were exposed toCoCl2 (100 mM) for different time periods as described
(Namiki et al., 1995). To assess vegf and gapdh transcript levels under
hypoxia, cellswere exposed toCoCl2 (100mM) for 24 hr, and transcripts
were determined by real-time RT-PCR analysis. Phosphorylation of
VEGFR2 under hypoxia was measured after exposure to CoCl2
(100 mM) for 24 hr in the presence or absence of sodium orthovanadate
(Na3VO4). Phosphorylation of VEGFR2 was performed as previously
described (Lee et al., 2005). To block VEGF signaling, cells were either
preincubated with SU4312 at 37C overnight, or VEGF was preincu-
bated with Avastin at 37C overnight. VEGFR2 phosphorylation was
determined by immunoprecipitating cell lysates with 4G-10 antibody
(Upstate, NY) and analyzing by western blot with anti-phosphotyrosine
antibody (Cell Signaling, MA) as described (Lee et al., 2005). To assess
the cell growth during blocking of VEGF signaling, cells were incubated
with either SU4312 or Avastin or both at 37C, and viable cells were de-
termined using CCK-8 kit. For coculture experiments, endothelial cells
were stained with CellTracker Red CMTPX or Cell Tracker Green BOD-
IFY (Molecular Probe, CA) following manufacturers’ protocol.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online
at http://www.cell.com/cgi/content/full/130/4/691/DC1/.
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